Heartseed Inc.
Stock Price Chart
2026/09/21 UpdatedPrice Trend
2026/09/21 UpdatedPrice & Trading Details
2026/09/21 UpdatedPRICE
TRADING
Analyst Recommendations 1 analysts
Updated 2026/09/01Shareholder Composition
Updated 2026/09/01Financial Performance
2026/09/20 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥499M | ¥345M | ¥874M | ¥3,027M |
| Gross Profit | ¥499M | ¥345M | ¥874M | ¥3,027M |
| Operating Income | -¥1,459M | -¥1,460M | -¥1,039M | ¥272M |
| Pretax Income | -¥1,409M | -¥1,456M | -¥818M | ¥289M |
| Net Income | -¥1,413M | -¥1,474M | -¥813M | ¥191M |
| EPS | -¥64.22 | -¥106.81 | -¥49.43 | - |
| Operating Margin | -292.27% | -423.41% | -118.91% | 8.99% |
| Balance Sheet | ||||
| Total Assets | ¥4,936M | ¥5,720M | ¥7,068M | ¥7,676M |
| Total Equity | ¥4,728M | ¥5,270M | ¥6,623M | ¥7,195M |
| Total Liabilities | ¥208M | ¥450M | ¥444M | ¥481M |
| Cash | ¥3,988M | ¥4,588M | ¥5,297M | ¥6,836M |
| Interest-bearing Debt | ¥31M | ¥12M | ¥5M | ¥0M |
| Equity Ratio | 95.78% | 92.13% | 93.71% | 93.74% |
| D/E Ratio | 0.01 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | -¥1,922M | -¥798M | -¥1,343M | ¥1,081M |
| Investing CF | -¥1M | -¥426M | -¥67M | ¥73M |
| Financing CF | -¥22M | ¥1,848M | ¥2,119M | ¥376M |
| Free CF | -¥1,922M | -¥1,126M | -¥1,357M | ¥1,052M |
| Efficiency | ||||
| ROE | -29.88% | -27.96% | -12.27% | 2.65% |
| ROA | -28.62% | -25.76% | -11.50% | 2.48% |
Latest IR Information
-
No IR information found for this company.
Searched stock code: 219A
Latest News (5 items)
-
Average Analyst Rating: strong_buy
Average Target Price: ¥4,000
Rating Score: 1.00 (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Heartseed Inc. develops and commercializes iPS cell-derived cardiomyocyte replacement therapy for heart failure. The company's lead product is HS-001 for heart failure with reduced ejection fraction indications, including dilated cardiomyopathy, old myocardial infraction, and dilated phase of hypertrophic cardiomyopathy. It also develops products using autologous iPSC and HLA knock-out iPSC. In addition, the company offers differentiation induction, mass culture, purification, and myocardial globule production technology. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.
